.”If the data stack up from 10 pivotal Phase III studies reporting results in 2018, the new drug could grab more than $5 billion in annual sales, Deutsche Bank analysts believe. “Once an oral is available I think there will PVC injection molding machine be significant interest in it.N) Januvia will report later in 2018.But making patients wait half an hour for breakfast could affect adherence and is a concern for investors - as is the question of what Novo will charge for a drug that may perform as well as a pricey injection but looks like rival pills that cost half as much.Getting this far with oral GLP is already a notable achievement, especially after an earlier oral insulin project was abandoned as uneconomic in 2016.Novo’s nearest rival in developing an oral GLP-1 is Israel’s Oramed (ORMP.“It will certainly be welcomed by those patients who prefer to go without their breakfast for half an hour rather than have an injection,” said Bailey.”That may be sour grapes by Novo’s arch-rival, whose own work on developing an oral GLP-1 is only at the preclinical stage.But Clifford Bailey, professor of clinical science at Britain’s Aston University and Dr.
While diabetics with advanced disease need daily insulin shots, those at a less serious stage start on simple tablets, with GLP-1s added as a potent new option since 2005.Rivals, especially Eli Lilly (LLY.A new treatmentDoctors hope oral semaglutide will provide a new weapon to tackle diabetes earlier with a highly effective therapy.What is oral semaglutide?But oral semaglutide is no simple tablet.CO) - the world’s biggest insulin maker - wants to prove this year it can transform the diabetes market with a pill.Most analysts expect oral semaglutide to beat these rivals in controlling both blood sugar and weight. insurers and cost-conscious European healthcare systems.What’s more, the drug must be in close contact with the stomach wall, which means patients cannot eat for 30 minutes after taking it and the pill can also cause nausea, raising questions about its practicality.“The highest limit of where we could consider taking the pricing would be injectable GLP-1 and the lowest level would be somewhere in between current oral drugs and injectable GLP-1,” Thomsen said.If Novo gets over the pricing hurdle, Bailey and Gaglia believe the new pill is set to reshuffle treatment regimens, with oral semaglutide being used as a second or third treatment option after cheap, generic metformin.